HB-2198

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameHB-2198
Drug Alias NameHB-2198HB2198
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulators
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus NephritisLupus Vulgaris
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHinge Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesHinge Bio IncKyorin Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLupus NephritisLupus Vulgaris
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A